硫酸长春地辛结构式
|
常用名 | 硫酸长春地辛 | 英文名 | Vindesine sulfate |
---|---|---|---|---|
CAS号 | 59917-39-4 | 分子量 | 852.00 | |
密度 | 1.41 g/cm3 | 沸点 | N/A | |
分子式 | C43H57N5O11S | 熔点 | >250ºC | |
MSDS | N/A | 闪点 | N/A |
硫酸长春地辛用途硫酸长春地辛是一种有效的微管蛋白抑制剂,Ki为0.110µM。硫酸长春地辛在体外具有抗增殖作用。硫酸长春地辛在体内具有抗肿瘤作用[1]。 |
中文名 | 硫酸长春地辛 |
---|---|
英文名 | vindesine sulfate |
英文别名 | 更多 |
描述 | 硫酸长春地辛是一种有效的微管蛋白抑制剂,Ki为0.110µM。硫酸长春地辛在体外具有抗增殖作用。硫酸长春地辛在体内具有抗肿瘤作用[1]。 |
---|---|
相关类别 | |
体外研究 | 硫酸长春地辛抑制L细胞生长,在40 nM处显示约25%的抑制作用【1】。 |
参考文献 |
密度 | 1.41 g/cm3 |
---|---|
熔点 | >250ºC |
分子式 | C43H57N5O11S |
分子量 | 852.00 |
精确质量 | 851.377502 |
PSA | 247.80000 |
LogP | 3.80150 |
外观性状 | 非晶形的固体 |
储存条件 | 2-8°C |
水溶解性 | deionized water: ≥50mg/mL |
危害码 (欧洲) | Xn: Harmful; |
---|---|
风险声明 (欧洲) | R40 |
安全声明 (欧洲) | 26-36 |
危险品运输编码 | UN 1544 |
RTECS号 | YY8090000 |
包装等级 | II |
危险类别 | 6.1(a) |
海关编码 | 2942000000 |
海关编码 | 2942000000 |
---|
Validated HILIC-MS/MS assay for determination of vindesine in human plasma: Application to a population pharmacokinetic study
J. Pharm. Biomed. Anal. 96 , 31-6, (2014) Mean plasma concentration–time profiles of intravenous injection of 3mg Vindesine Sulfate for Injection to 100 unrelated Chinese Han subjects with hematological malignant disorders. |
|
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
J. Clin. Oncol. 32(35) , 3996-4003, (2014) To determine whether any tumor biomarkers could account for the survival advantage observed in the LNH 03-2B trial among patients with diffuse large B-cell lymphoma (DLBCL) and low-intermediate risk a... |
|
Reovirus cell entry requires functional microtubules.
MBio 4 , (2013) Mammalian reovirus binds to cell-surface glycans and junctional adhesion molecule A and enters cells by receptor-mediated endocytosis in a process dependent on β1 integrin. Within the endocytic compar... |
2H-3,7-Methanoazacycloundecino[5,4-b]indole-9-carboxylic acid, 9-[(2β,3β,4β,5α,12β,19α)-3-(aminocarbonyl)-6,7-didehydro-3,4-dihydroxy-16-methoxy-1-methylaspidospermidin-15-yl]-5-et hyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-, methyl ester, (5S,7S,9S)-, sulfate (1:1) (salt) |
methyl (5S,7S,9S)-9-[(2β,3β,4β,5α,12β,19α)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate sulfate (1:1) |
Vindesine Sulfate Salt |
2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylic acid, 9-[(2β,3β,4β,5α,12β,19α)-3-(aminocarbonyl)-6,7-didehydro-3,4-dihydroxy-16-methoxy-1-methylaspidospermidin-15-yl]-5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-, methyl ester, (5S,7S,9S)-, sulfate (1:1) (salt) |
Vindesine sulphate |
Methyl (13S,15S,17S)-13-[(2β,3β,4β,5α,12β,19α)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.0.0]nonadeca-4(12),5,7,9-tetraene-13-carboxylate sulfate (1:1) |